ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Colgate Palmolive and BioNTech side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Colgate PalmoliveBioNTech
studies on the registry121124
open to participants now1432
phase 3 studies under way79
reach primary completion within a year811
programswith a study of their own in two years3523

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseColgate PalmoliveBioNTech
Phase 100%

BioNTech: 4 of its 23 programs at phase 1

  1. BNT168phase 1
  2. BNT3219phase 1
  3. BNT351phase 1
  4. CV09070101phase 1
17%
Phase 2

Colgate Palmolive: 1 of its 35 programs at phase 2

  1. Vitamin C toothpastephase 2
3%
65%
Phase 371%

BioNTech: 3 of its 23 programs at phase 3

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3
  3. trastuzumab pamirtecanphase 3
13%
Approved, new studies

Colgate Palmolive: 9 of its 35 programs at approved, new studies

  1. Tin Fluoridesapproved, new study
  2. Cetylpyridiniumapproved, new study
  3. zinc lactateapproved, new study
  4. cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwashapproved, new study
  5. 0.09% CPC + Zinc Lactate Mouthwashapproved, new study

and 4 more — sign in to see them all

26%

BioNTech: 1 of its 23 programs at approved, new studies

  1. BNT162 Vaccineapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Colgate Palmolive9 readouts · 9 phase 3

Colgate Palmolive, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Colgate SNaP Total 10/10, 1.5 Tauratephase 3 · Nov 0 · NCT07605338

Colgate Palmolive, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. 0.09% CPC + Zinc Lactate Mouthwashapproved, new study · Dec 15 · NCT07880509
  2. Prevident 5000ppm Booster Plus Toothpasteapproved, new study · Dec 20 · NCT07819370

Colgate Palmolive, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. 0.45% SnF HW with NaF (1450 F)phase 3 · Jan 0 · NCT07842991
··

Colgate Palmolive, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Silica Free Meridolphase 3 · Apr 0 · NCT07842978

Colgate Palmolive, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oil-balancing sunscreenapproved, new study · May 0 · NCT07932288
···

Colgate Palmolive, Sep ’27: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwashapproved, new study · Sep 0 · NCT07807397
  2. sodium fluoride 5000 ppmapproved, new study · Sep 0 · NCT07807397
  3. Tin Fluoridesapproved, new study · Sep 0 · NCT07807397
·
BioNTech4 readouts · 1 phase 3

BioNTech, Nov ’26: 1 program whose next study reaches primary completion

  1. BNT351phase 1 · Nov 0 · NCT07392372
·

BioNTech, Jan ’27: 1 program whose next study reaches primary completion

  1. pumitamigphase 3 · Jan 1 · NCT05879055
··

BioNTech, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. BNT162 Vaccineapproved, new study · Apr 12 · NCT07798648
·

BioNTech, Jun ’27: 1 program whose next study reaches primary completion

  1. BNT166Aphase 2 · Jun 0 · NCT07379580
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Colgate Palmolive

New programs 8

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

BioNTech

New programs 2

  • BNT3219phase 1 · first study · Oct 19
  • BNT3210phase 2 · first study · Oct 15

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Where they overlap

No condition where two of them both have programs.

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Colgate Palmolive 0 of 35 · BioNTech 11 of 23 programs (6 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.